Skip to main content
. Author manuscript; available in PMC: 2014 Feb 10.
Published in final edited form as: Pigment Cell Melanoma Res. 2012 Nov 6;26(1):97–112. doi: 10.1111/pcmr.12031

Figure 4. The effect of knockdown of GNPAT, SUMO1, SPINT2, FLI1, and SSX1 on cell growth and the efficacy of CDDO-Me in human melanoma cells.

Figure 4

Melanoma cell lines plated in 96-well plates were transfected with siRNA pools (100 nM) targeting GNPAT, SUMO1, SPINT2, FLI1, and SSX1 for 4 h, followed by treatment with CDDO-Me at 50 nM (a) or the indicated doses (b). After 72 h, cell viability was determined by MTT assays. The percent of cell viability in each treatment group was normalized to negative control, cells treated with si-NSC. Each experiment for cell viability assay was carried out three times. Each bar denotes mean ± SD of three experiments. CM, CDDO-Me; D-FECT 3, transfection reagent.